Silverarc Capital Management, LLC 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Silverarc Capital Management, LLC disclosed 67 US equity positions worth $478.6m in its Q1 2025 13F filing. The largest position was VRNA at 7.2% of the reported book, followed by MERUS N V and NUVALENT INC. Against the Q4 2024 filing, it opened 16 new positions, added to 25 and reduced 9 among the top 50 holdings.
What did Silverarc Capital Management, LLC own in Q1 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | VRNA VERONA PHARMA PLC | 7.2% | $34.7m | 545,872 | 6% | added | |
| 2 | MERUS N V | 7.1% | $34.1m | 811,021 | 19% | added | |
| 3 | NUVALENT INC | 6.5% | $31.1m | 439,018 | 10% | added | |
| 4 | AKERO THERAPEUTICS INC | 6.1% | $29.1m | 719,992 | -3% | reduced | |
| 5 | INSM INSMED INC | Healthcare | 5.1% | $24.5m | 321,366 | -14% | reduced |
| 6 | 4XC1 KALVISTA PHARMACEUTICALS INC | 4.1% | $19.6m | 1,698,984 | 178% | added | |
| 7 | VCYT VERACYTE INC | Healthcare | 3.9% | $18.8m | 633,832 | 26% | added |
| 8 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.7% | $17.9m | 337,605 | 23% | added |
| 9 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.4% | $16.1m | 1,309,224 | 6% | added |
| 10 | URGN UROGEN PHARMA LTD | Healthcare | 3.2% | $15.3m | 1,381,158 | 23% | added |
| 11 | RNAGBP AVIDITY BIOSCIENCES INC | 2.5% | $12.1m | 411,312 | -24% | reduced | |
| 12 | SLNOEUR SOLENO THERAPEUTICS INC | 2.5% | $11.9m | 166,417 | – | new | |
| 13 | ASND ASCENDIS PHARMA A/S | Healthcare | 2.5% | $11.8m | 75,751 | 47% | added |
| 14 | IRON DISC MEDICINE INC | Healthcare | 2.5% | $11.7m | 236,471 | 114% | added |
| 15 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 2.4% | $11.5m | 2,060,240 | 75% | added |
| 16 | ETNBGBP 89BIO INC | 2.3% | $11.0m | 1,510,498 | 1465% | added | |
| 17 | ERAS ERASCA INC | Healthcare | 2.1% | $10.1m | 7,367,996 | -2% | reduced |
| 18 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.8% | $8.5m | 1,050,374 | 73% | added |
| 19 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.7% | $8.0m | 72,583 | – | new |
| 20 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.5% | $7.3m | 408,849 | 47% | added |
| 21 | GOSS GOSSAMER BIO INC | Healthcare | 1.5% | $7.0m | 6,320,684 | 2% | added |
| 22 | GILD GILEAD SCIENCES INC | Healthcare | 1.5% | $7.0m | 62,029 | 520% | added |
| 23 | HELIX ACQUISITION CORP II | 1.4% | $6.9m | 613,393 | 19% | added | |
| 24 | ELUT ELUTIA INC | 1.4% | $6.8m | 2,670,056 | 50% | added | |
| 25 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.3% | $6.3m | 166,074 | 129% | added |
| 26 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.1% | $5.4m | 338,354 | – | new |
| 27 | CGEN COMPUGEN LTD | Healthcare | 0.9% | $4.2m | 2,895,430 | 78% | added |
| 28 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 0.9% | $4.2m | 81,331 | 23% | added |
| 29 | ALKS ALKERMES PLC | Healthcare | 0.9% | $4.1m | 124,871 | – | new |
| 30 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 0.8% | $4.0m | 551,570 | – | new |
| 31 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 0.8% | $3.8m | 111,000 | – | new |
| 32 | KURA KURA ONCOLOGY INC | Healthcare | 0.8% | $3.8m | 581,369 | – | new |
| 33 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.8% | $3.7m | 205,962 | -22% | reduced |
| 34 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.7% | $3.5m | 190,334 | – | new |
| 35 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 0.7% | $3.4m | 10,344 | – | new |
| 36 | CERS CERUS CORP | Healthcare | 0.7% | $3.4m | 2,456,537 | 55% | added |
| 37 | TELA TELA BIO INC | 0.7% | $3.4m | 2,771,288 | -10% | reduced | |
| 38 | CNTA CENTESSA PHARMACEUTICALS PLC | 0.7% | $3.3m | 232,758 | -61% | reduced | |
| 39 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.7% | $3.3m | 530,000 | -28% | reduced |
| 40 | 2655787D BLUEPRINT MEDICINES CORP | 0.7% | $3.3m | 37,345 | – | new | |
| 41 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.7% | $3.3m | 188,069 | 23% | added |
| 42 | BENITEC BIOPHARMA INC | 0.7% | $3.3m | 250,000 | – | new | |
| 43 | LQDA LIQUIDIA CORPORATION | Healthcare | 0.7% | $3.2m | 214,057 | – | new |
| 44 | PTCT PTC THERAPEUTICS INC | Healthcare | 0.6% | $3.1m | 60,389 | – | new |
| 45 | METSERA INC | 0.6% | $3.1m | 112,759 | – | new | |
| 46 | BDSX BIODESIX INC | 0.5% | $2.6m | 4,098,406 | -5% | reduced | |
| 47 | DCTH DELCATH SYS INC | 0.5% | $2.4m | 191,470 | 23% | added | |
| 48 | QURE UNIQURE NV | 0.5% | $2.2m | 203,400 | 103% | added | |
| 49 | KINIKSA PHARMACEUTICALS INTL | 0.4% | $2.0m | 88,215 | – | new | |
| 50 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.3% | $1.7m | 452,239 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.